Eyenovia begins progressive myopia trial

Eyenovia has enrolled the first patient in a phase 3 study of MicroPine for the treatment of progressive myopia, according to a press release.
The multicenter, double-masked CHAPERONE study will evaluate MicroPine, a topical atropine micro-formulation delivered with Optejet, the company’s piezo-print delivery technology. It will include more than 400 children between the ages of 3 and 12 years, and the primary endpoint is a change in refractive error from baseline to 36 months in two concentrations of MicroPine and placebo, the release said.
“This program could set some

Full Story →